BIO-Europe Spring®
The thirteenth annual BIO-Europe Spring® conference is the premier springtime partnering conference for the biotechnology industry. For its 2019 edition, BIO-Europe Spring comes to Vienna, Austria on March 25–27, 2019.
The conference annually attracts the international “who’s who” from biotech, pharma and finance for three days of high caliber networking. BIO-Europe Spring’s world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Attend BIO-Europe Spring and experience how you can have more partnering meetings in the three days of the conference than in the rest of the year.
Based on attendance at previous events, BIO-Europe Spring 2019 will bring together close to 2,500 executives from biotechnology, pharmaceutical and finance companies from around the world, who will engage in over 14,000 partnering meetings.
Partnering at BIO-Europe Spring is powered by partneringONE®, the leading conference solution for helping life science delegates meet efficiently and effectively. partneringONE has the unique ability to manage the complex interactions between thousands of executives from many different companies.
Contact Details:
E-mail: smunro@ebdgroup.com
Click here for more information: BIO-Europe Spring®
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
